MicroPort Endovascular MedTech Ltd

Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.

Pas encore d'analyse sur cette valeur dans votre langue.